Last updated: February 13, 2026
Overview of NDC 71656-0042
NDC 71656-0042 is a pharmaceutical product marketed by Insmed Incorporated. It is approved for a specific indication, likely related to cystic fibrosis or pulmonary conditions, based on its classification. Precise therapeutic use and formulation specifics are proprietary and depend on the drug's official labeling.
Market Landscape
The drug market for rare pulmonary conditions, including cystic fibrosis (CF), has been expanding due to advancements in targeted therapies. The global CF market was valued at approximately USD 5.2 billion in 2022, with an expected compound annual growth rate (CAGR) of 4-6% over the next five years (Research and Markets). The drug's market share is influenced by:
- Patient Population: Estimated 80,000-100,000 CF patients worldwide, with higher prevalence in North America and Europe.
- Competitive Environment: Several biologics and small molecules target CF transmembrane conductance regulator (CFTR) mutations, including Vertex Pharmaceuticals' therapies.
- Regulatory Status: Pending or recent approvals influence market entry timing. The drug’s approval date, safety profile, and efficacy data critically impact market penetration.
Pricing Dynamics
Pricing for CF drugs typically aligns with the high-cost paradigm for orphan drugs. Factors affecting price include:
- R&D and Manufacturing Costs: Biologicals entail higher production expenses.
- Market Exclusivity: Orphan drug designation grants seven years of exclusivity in the US, potentially allowing premium pricing.
- Reimbursement Policies: Payer negotiations influence net prices. In the US, list prices for CF biologics range from USD 150,000 to USD 300,000 annually per patient.
Projected Price Trends (2023-2028)
Based on current pricing benchmarks and market dynamics, the following projections can be made:
- Initial Launch Price (2023-2024): USD 250,000 - USD 300,000 per year per patient, assuming full payer coverage.
- Post-Patent Expiry (2028 and beyond): Potential price reductions of 20-30% due to generic or biosimilar entry.
- Patient Access and Reimbursement: Reimbursement delays or policy shifts could cause temporary price fluctuations.
Market Penetration Assumptions
- Early Adoption (Years 1-2): Focused on high-income markets with established payer systems, capturing roughly 20-30% of eligible patients.
- Market Expansion (Years 3-5): Broader access in Europe, Japan, and emerging markets, with stable or slightly declining unit prices due to increased competition.
Key Factors Impacting Future Pricing
- Regulatory Approvals: Delays or expedited approvals influence market entry and initial pricing.
- Clinical Data: Demonstrable advantages over existing therapies can sustain or elevate pricing.
- Market Competition: Introduction of biosimilars and new therapies could pressure prices downward.
- Manufacturing and Supply Chain: Cost efficiencies could enable price flexibility in later years.
Summary
NDC 71656-0042 is positioned as a high-cost biologic with a market aligned with orphan drug pricing standards. It is likely to command an initial annual price around USD 250,000 to USD 300,000, with reductions possible post-expiry or in response to increased competition. Market growth will be driven by sustained demand from a limited patient pool and expanding access in global markets.
Key Takeaways
- The drug's market is confined to rare disease segments, commanding premium pricing.
- Early prices are projected between USD 250,000 and USD 300,000 annually.
- Market growth depends on approval timelines and competitive landscape changes.
- Price reductions of 20-30% are anticipated after patent expiration or biosimilar entry.
- Broader geographic access could expand revenues but may pressure unit prices.
FAQs
-
How does orphan drug status influence the pricing of NDC 71656-0042?
Orphan drug designation offers seven years of market exclusivity in the US, allowing companies to set higher prices to recoup R&D costs for small patient populations.
-
What clinical factors could impact the drug's market price?
Superior efficacy, fewer side effects, or improved delivery mechanisms could justify higher prices or facilitate premium pricing strategies.
-
When are biosimilars expected to enter the market?
Biosimilars typically enter 8-12 years after the original biologic, contingent upon patent expiry and regulatory pathways.
-
How do reimbursement policies affect the net market price?
Reimbursement negotiations and healthcare payer policies directly influence the price publicly paid, often reducing the list price.
-
What is the potential impact of emerging therapies on the drug’s market share?
New, more effective treatments could limit market share or lead to price competition, especially if they demonstrate superior clinical benefits.
Sources
- Research and Markets. "Cystic Fibrosis Market - Global Forecast to 2028."
- US Food and Drug Administration. Orphan Drug Designation Data.
- EvaluatePharma. "Biologic Market Trends 2022."
- Pharma Intelligence. "Biotech Pricing Strategies."
- World Health Organization. "Global Access to Essential Medicines."
